Home › NCT06600659

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

A Pilot Study to Establish Incidence and Characteristics of Patients at Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase

Who can join

Ages 1 and older · All sexes

Inclusion Criteria:

* Followed by pediatric hematology/oncology
* Receiving recombinant Erwinia asparaginase for treatment of malignancy

Exclusion Criteria:

* Patients \< 1 year of age
* Patients who have previously received recombinant Erwinia asparaginase within the past two weeks

About the study

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

What is being tested

• Non-Interventional Study (other)

Sponsor: Mayo Clinic · Participants: 10 · Started: Nov 2, 2023

Contact the study team

• Clinical Trials Referral Office · Phone: 855-776-0015

Official record on ClinicalTrials.gov — NCT06600659

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.